PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we investigated the influence of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective ligands (PD-1 ligand 1 [PD-L1], PD-L2, CD80, and CD86) on MDSCs. We demonstrate that MDSCs at the tumor site show a differential expression of PD-L1 as compared with MDSCs from peripheral lymphoid organ (spleen). Hypoxia caused a rapid, dramatic, and selective up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice. This was not limited to MDSCs, as hypoxia also significantly increased the expression of PD-L1 on macrophages, dendritic cells, and tumor cells. Furthermore, PD-L1 up-regulation under hypoxia was dependent on hypoxia-inducible factor-1α (HIF-1α) but not HIF-2α. Chromatin immunoprecipitation and luciferase reporter assay revealed direct binding of HIF-1α to a transcriptionally active hypoxia-response element (HRE) in the PD-L1 proximal promoter. Blockade of PD-L1 under hypoxia enhanced MDSC-mediated T cell activation and was accompanied by the down-regulation of MDSCs IL-6 and IL-10. Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs. Simultaneous blockade of PD-L1 along with inhibition of HIF-1α may thus represent a novel approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Blockade of PD-L1 under hypoxia down-regulates MDSC IL-6 and IL-10 and enhances T cell proliferation and function. MDSCs isolated from spleens of B16-F10 tumor-bearing mice were pretreated for 30 min on ice with 5 µg/ml control antibody (IgG) or antibody against PD-L1 (PDL1 Block) and co-cultured with splenocytes under normoxia and hypoxia for 72 h. (A and B) Effect of MDSC on proliferation of splenocytes stimulated with (A) anti-CD3/CD28 coated beads or (B) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured in triplicates by [3H]thymidine incorporation and expressed as counts per minute (CPM). (C and D) MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (C) CD3+CD8+ IFN-γ+ and (D) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (**, P < 0.005; ***, P < 0.0005). Three separate experiments (in triplicates) with the same results were performed. Error bars indicate SD. (E) SYBR-GREEN RT-qPCR was performed to evaluate the mRNA expression levels of Ldha, Car-9, Arg-1, Nos2, Ncf-1, and Cybb-1. (F) Arginase enzymatic activity measured in MDSCs under indicated conditions. (G) After 72 h of MDSC co-culture with splenocytes, supernatants were collected and assayed for nitrites. Data represents three independent experiments with SD. (H) SYBR Green RT-qPCR was performed for expression levels of IL6, IL10, Il12p70, and Tgfb1 under the indicated conditions. IL-6, IL-10, IL-12p70, and TGF-β1 cytokine production and secretion was detected by (I and J) intracellular FACS staining (isotype control is gray-shaded histogram) and (K) ELISA, respectively. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). The experiment was performed in triplicates and repeated three times with the same results. Error bars indicate SD. (L–O) MDSCs isolated from spleens of B16-F10 tumor-bearing mice were co-cultured with splenocytes under normoxia and hypoxia for 72 h in the presence of either 10 µg/ml control antibody (IgG), anti–mouse IL-6 Functional Grade Purified neutralizing antibody (IL-6 Block) or anti–mouse IL-10 Functional Grade Purified neutralizing antibody (IL-10 Block). Effect of MDSCs on proliferation of splenocytes stimulated with (L) anti-CD3/CD28–coated beads or (M) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured as indicated above. MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (N) CD3+CD8+ IFN-γ+ and (O) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](https://figures.cochat.ai/paper-figures/2ba8a156b22c410c8802e99a6f19ff08/pd-l1-is-a-novel-direct-target-of-hif-1-and-its-blockade-under-hypoxia-enhanced-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to regulating components of the innate immune response, the HIFs have been linked to modulation of the adaptive immune response through upregulation of both co-inhibitory (eg. PD-L1 and CTLA4) and co-stimulatory receptors (eg. 4–1BB, OX40) on activated T cells [80, 81].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
From Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A large body of preclinical and clinical data indicates that antibody blockade of immune checkpoints can significantly enhance antitumor immunity (Pardoll, 2012; West et al., 2013).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are a heterogeneous group of relatively immature myeloid cells and several studies have described mechanisms of MDSCmediated immune suppression (Gabrilovich et al., 2012).”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“PD-1, a cell surface glycoprotein with a structure similar to cytotoxic T lymphocyte antigen 4 (CTLA-4), belongs to the B7 family of co-stimulatory/co-inhibitory molecules and plays a key part in immune regulation (Greenwald et al., 2005).”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 3×
“It is important to underline that our results are in complete agreement with previous findings by Youn et al. (2008), indicating that normoxic blockade of PD-L1 did not eliminate suppressive activity of MDSCs.”
BackgroundMethodResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 12×
“2 I) and DCs (CD11c+; Fig.”
BackgroundResultInfluentialPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · cited 6×
“As shown previously by Corzo et al. (2010), we observed higher levels of Arg-1 gene expression (Fig.”
BackgroundInfluentialOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993 · cited 1×
“2014 Vol. 211 No. 5 781-790 www.jem.org/cgi/doi/10.1084/jem.20131916 781 Brief Definit ive Report Hypoxia is a common feature of solid tumors (Semenza, 2011).”
BackgroundInfluential
Cited by
Items 101–200 of 1,009
Molecular therapies for HCC: Looking outside the box
Faivre, S., Rimassa, L., & Finn, R. S. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.010 · Cited by 326
Metabolic regulation of inflammation
Gaber, T., Strehl, C., & Buttgereit, F. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.37 · Cited by 320
Berchem, G., Noman, M. Z., Bosseler, M., Paggetti, J., Baconnais, S., Le cam, E., Nanbakhsh, A., Moussay, E., Mami-Chouaib, F., Janji, B., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1062968 · Cited by 317
“Flow cytometry was performed using a LSR-II flow cytometer (BD Biosciences) and indicated antibodies.(7) Data were further analyzed by FACS DIVA 7.”
BackgroundMethodSelf-citationWang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01820-7 · Cited by 315
“Under hypoxic conditions, inhibition of PD-L1 promotes MDSCmediated T cell activation along with decreased MDSC production of IL-6 and IL-10 [65].”
BackgroundInfluentialCAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Rodriguez-Garcia, A., Palazon, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01109 · Cited by 312
“Hypoxia and HIF promote the expression of program death ligand 1 (PD-L1) (86, 124) and adenosine levels (125, 126), as well as the recruitment of regulatory T (Treg) cells in the TME (127), all of which are known to inhibit T cell responses.”
BackgroundIL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J., & Umansky, V. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 309
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00386 · Cited by 305
“Extrinsic Factors Influencing the Expression of PD-L1 The main regulators of PD-L1 are the interferon-γ (83), inflammatory cytokines such as IL-17 (84) and TNF-α (84), TGF-β1 (85), and HIF-1α (86).”
BackgroundHIF Inhibitors: Status of Current Clinical Development
Fallah, J., & Rini, B. I. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0752-z · Cited by 308
The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1
Janse van Rensburg, H. J., Azad, T., Ling, M., Hao, Y., Snetsinger, B., Khanal, P., Minassian, L. M., Graham, C. H., Rauh, M. J., & Yang, X. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3139 · Cited by 306
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Anfray, C., Ummarino, A., Andón, F. T., & Allavena, P. (2019) · Cells · doi:10.3390/cells9010046 · Cited by 304
“In response to hypoxia and to specific cytokines, TAMs overexpress the PD‐1 ligands (PD‐L1 and PD‐L2), as well as the CTLA‐4 ligand [36,37].”
BackgroundGong, X., Li, X., Jiang, T., Xie, H., Zhu, Z., Zhou, F., & Zhou, C. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.014 · Cited by 303
“Studies have also shown that transcriptional factors and epigenetic factors also drive the expression of PD-L1.(29,44) Our study has also demonstrated that conventionally fractionated radiotherapy may lead to upregulation of PD-L1 expression on tumor cells through activation of the PI3K/AKT and STAT3 pathways.”
BackgroundInfluentialSamanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302
“Hypoxia induces PDL1 expression in tumor and immune cells in an HIF-1–dependent manner (28, 29).”
BackgroundThe intracellular signalosome of PD-L1 in cancer cells
Escors, D., Gato-Cañas, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 292
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
“HIF-1α also enhanced the expression of PD-L1, thereby promoting the suppressive capacities of MDSC and their interaction with Treg [168].”
BackgroundZerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 292
“Indeed, HIF-1a transcriptionally regulates PD-L1 expression by binding on HRE of its promoter [66].”
BackgroundYang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01371 · Cited by 291
Combining microenvironment normalization strategies to improve cancer immunotherapy
Mpekris, F., Voutouri, C., Baish, J. W., Duda, D. G., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919764117 · Cited by 286
“Specifically, hypoxia up-regulates immune checkpoints (11, 12), reprograms tumor-associated macrophages (TAMs) from an immunosupportive M1-like phenotype toward an immunosuppressive M2-like state, and may hinder the Significance Immunotherapy has changed the standard of care in cancer treatment,…”
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
“For example, oncogenic c-Jun (AP-1) and STAT3 signaling (53), and hypoxia-inducible factor HIF-1α (54) upregulate PD-L1 expression transcriptionally; the oncogenic epigenetic writer EZH2 (55) and epigenetic reader BET4 upregulate PD-L1 (56), whereas the epigenetic eraser histone deacetylase downregulates PD-L1 express…”
BackgroundHypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells
Colwell, N., Larion, M., Giles, A. J., Seldomridge, A. N., Sizdahkhani, S., Gilbert, M. R., & Park, D. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now258 · Cited by 284
Up-down regulation of HIF-1α in cancer progression
Rashid, M., Zadeh, L. R., Baradaran, B., Molavi, O., Ghesmati, Z., Sabzichi, M., & Ramezani, F. (2021) · Gene · doi:10.1016/j.gene.2021.145796 · Cited by 283
The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis
Nishida, A., & Andoh, A. (2025) · Cells · doi:10.3390/cells14070488 · Cited by 270
Zhang, H., Ye, Y.-L., Li, M.-X., Ye, S.-B., Huang, W.-R., Cai, T.-T., He, J., Peng, J.-Y., Duan, T.-H., Cui, J., et al. (2017) · Oncogene · doi:10.1038/onc.2016.367 · Cited by 278
Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment
Ridder, K., Sevko, A., Heide, J., Dams, M., Rupp, A.-K., Macas, J., Starmann, J., Tjwa, M., Plate, K. H., Sültmann, H., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008371 · Cited by 276
“This ligand has been described to be expressed on MDSCs and tumor cells20,21 and to induce T cell anergy by binding to its receptor PD-1.”
BackgroundIrreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
Zhao, J., Wen, X., Tian, L., Li, T., Xu, C., Wen, X., Melancon, M. P., Gupta, S., Shen, B., Peng, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08782-1 · Cited by 272
Metabolic reprogramming of macrophages during infections and cancer
Wang, S., Liu, R., Yu, Q., Dong, L., Bi, Y., & Liu, G. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.015 · Cited by 272
Wu, Q., Zhou, W., Yin, S., Zhou, Y., Chen, T., Qian, J., Su, R., Hong, L., Lu, H., Zhang, F., et al. (2019) · Hepatology · doi:10.1002/hep.30593 · Cited by 269
“Given that PD-L1, a member of the B7 family, can respond to hypoxia,(26,27) the”
BackgroundHypoxia-Driven Immune Escape in the Tumor Microenvironment
Vito, A., El-Sayes, N., & Mossman, K. (2020) · Cells · doi:10.3390/cells9040992 · Cited by 270
“This upregulation was shown to be dependent on HIF-1α, but not HIF-2α [94].”
BackgroundMeng, L., Cheng, Y., Tong, X., Gan, S., Ding, Y., Zhang, Y., Wang, C., Xu, L., Zhu, Y., Wu, J., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b03590 · Cited by 268
The role of hypoxia‐inducible factor 1 in tumor immune evasion
You, L., Wu, W., Wang, X., Fang, L., Adam, V., Nepovimova, E., Wu, Q., & Kuca, K. (2021) · Medicinal Research Reviews · doi:10.1002/med.21771 · Cited by 265
“PD‐L1 monoclonal antibody in response to hypoxia, MDSCs lost the ability to inhibit T cell function by increasing the ratio of interferon γ (IFN‐γ) CD8 and IFN‐γ CD4 T cells and decreasing the expression of IL‐6 and IL‐10.(72) Therefore, we suspect that there may be an irreversible process: blocking PD‐L1 under hypoxi…”
BackgroundInfluentialCancer Inflammation and Cytokines
Galdiero, M. R., Marone, G., & Mantovani, A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028662 · Cited by 267
“Macrophages can express PD-L1 and PD-L2, which can be upregulated under the influence of proinflammatory stimuli and hypoxia (Noman et al. 2014).”
BackgroundLi, L., Wang, L., Li, J., Fan, Z., Yang, L., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 266
“Previous studies reported the role of HIF-1 in regulating function and differentiation of MDSCs in the tumor microenvironment(49-51).”
BackgroundSong, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 261
“Interestingly, in numerous studies, elevation in PD-L1 expression is considered a consequence of hypoxia induced by antiangiogenic treatment (151) or independent of hypoxia or hypoxia-inducible factor 1α (HIF1α) (152, 153).”
BackgroundHarnessing innate immune pathways for therapeutic advancement in cancer
Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01765-9 · Cited by 255
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Kim, H. R., Ha, S.-J., Hong, M. H., Heo, S. J., Koh, Y. W., Choi, E. C., Kim, E. K., Pyo, K. H., Jung, I., Seo, D., et al. (2016) · Scientific Reports · doi:10.1038/srep36956 · Cited by 256
Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax7881 · Cited by 255
Self-citationExosome-orchestrated hypoxic tumor microenvironment
Meng, W., Hao, Y., He, C., Li, L., & Zhu, G. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0982-6 · Cited by 251
Noman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1263412 · Cited by 253
“Western blotting was performed as previously.(7)”
MethodSelf-citationRadiation-induced tumor immune microenvironments and potential targets for combination therapy
Guo, S., Yao, Y., Tang, Y., Xin, Z., Wu, D., Ni, C., Huang, J., Wei, Q., & Zhang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01462-z · Cited by 242
“In addition, HIF-1α can upregulate PD-L1 on MDSCs by binding to the PD-L1 promoter, which causes radioresistance by restraining the effect of CD8+ T cells.(135) Aggregation of MDSCs in the TME after RT is one of the main causes of radioresistance.”
BackgroundHypoxia as a driver of resistance to immunotherapy
Kopecka, J., Salaroglio, I. C., Perez-Ruiz, E., Sarmento-Ribeiro, A. B., Saponara, S., De Las Rivas, J., & Riganti, C. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100787 · Cited by 246
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
Jiang, H., Hegde, S., & DeNardo, D. G. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2003-1 · Cited by 242
“HIF-1α has been reported to influence MDSC function by regulating PD-L1 expression, suggesting blockade of PD-L1 along with inhibition of HIF-1α may represent a novel approach to target MDSCs as part of cancer immunotherapy in fibrotic tumors [59].”
Genetically engineered T cells for cancer immunotherapy
Li, D., Li, X., Zhou, W.-L., Huang, Y., Liang, X., Jiang, L., Yang, X., Sun, J., Li, Z., Han, W.-D., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0070-9 · Cited by 244
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
Sloas, C., Gill, S., & Klichinsky, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783305 · Cited by 241
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
“Intratumoural MDSCs can suppress T cell function (193) and thus may dampen the immune response and promote resistance to anti-PD-1 therapies.”
BackgroundThe influence of diet on anti-cancer immune responsiveness
Soldati, L., Di Renzo, L., Jirillo, E., Ascierto, P. A., Marincola, F. M., & De Lorenzo, A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1448-0 · Cited by 242
“Furthermore, TAMs express PD-1 ligand, which binds to PD-1 inhibiting Tc cell function [22].”
BackgroundLiu, Y., Liu, X., Zhang, N., Yin, M., Dong, J., Zeng, Q., Mao, G., Song, D., Liu, L., & Deng, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.014 · Cited by 237
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia
Ding, X.-C., Wang, L.-L., Zhang, X.-D., Xu, J.-L., Li, P.-F., Liang, H., Zhang, X.-B., Xie, L., Zhou, Z.-H., Yang, J., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01102-5 · Cited by 243
“These findings were consistent with the external central nervous system tumors [7, 8].”
MethodResultImmune checkpoints in the tumor microenvironment
Toor, S. M., Sasidharan Nair, V., Decock, J., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 236
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
Zheng, X., Fang, Z., Liu, X., Deng, S., Zhou, P., Wang, X., Zhang, C., Yin, R., Hu, H., Chen, X., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96582 · Cited by 239
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 237
Toledo, B., Zhu Chen, L., Paniagua-Sancho, M., Marchal, J. A., Perán, M., & Giovannetti, E. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01559-0 · Cited by 226
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Lu, C., Redd, P. S., Lee, J. R., Savage, N., & Liu, K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1247135 · Cited by 230
“The regulation of PD-L1 in MDSCs is much less studied.(62) It has been shown that PD-L1 expression in MDSCs is regulated by HIF-1a in the tumor microenvironment.”
BackgroundHypoxia and acidosis: immune suppressors and therapeutic targets
Damgaci, S., Ibrahim‐Hashim, A., Enriquez‐Navas, P. M., Pilon‐Thomas, S., Guvenis, A., & Gillies, R. J. (2018) · Immunology · doi:10.1111/imm.12917 · Cited by 231
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Zhang, J., Dang, F., Ren, J., & Wei, W. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.09.004 · Cited by 229
Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways
Sørensen, B. S., & Horsman, M. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00562 · Cited by 229
“A rapid and selective upregulation of PD-L1 is induced by hypoxia on MDSCs, and significant increased expression of PD-L1 on macrophages, dendritic cells and tumor cells, all due to HIF1 binding directly to the HRE in the PD-L1 proximal promoter (68).”
BackgroundCassetta, L., Baekkevold, E. S., Brandau, S., Bujko, A., Cassatella, M. A., Dorhoi, A., Krieg, C., Lin, A., Loré, K., Marini, O., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02302-2 · Cited by 224
Tamura, R., Tanaka, T., Akasaki, Y., Murayama, Y., Yoshida, K., & Sasaki, H. (2020) · Medical Oncology · doi:10.1007/s12032-019-1329-2 · Cited by 226
“HIF-1α upregulation directly drives recruitment of immature myeloid cells and Tregs, and fosters their phenotypic conversion into highly suppressive MDSCs and TAMs [58].”
BackgroundInfluentialThe intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells
Liu, N.-N., Yi, C.-X., Wei, L.-Q., Zhou, J.-A., Jiang, T., Hu, C.-C., Wang, L., Wang, Y.-Y., Zou, Y., Zhao, Y.-K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.012 · Cited by 223
Deng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224
“To address the concern that genetic ablation of Vista may interfere with expression of other checkpoints such as PD-L1, which is also hypoxia regulated (19), we used an antibody approach.”
BackgroundMethodResultInfluentialCurrent status of immune checkpoint inhibitors for gastric cancer
Kono, K., Nakajima, S., & Mimura, K. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01090-4 · Cited by 220
“The expression of PD-L1 on TAM might be triggered by cytokine stimulation and hypoxia [64, 65] and PD-L1 expression in stroma was significantly associated with dense infiltration of TAM in GC [63].”
BackgroundPhenotype, development, and biological function of myeloid-derived suppressor cells
Zhao, Y., Wu, T., Shao, S., Shi, B., & Zhao, Y. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1004983 · Cited by 220
“Hypoxia causes a rapid, dramatic, and selective upregulation of PD-L1 on splenic MDSCs in tumor-bearing mice.(73) Furthermore, the upregulation of PD-L1 is dependent on HIF1-a, but not HIF-2a.”
BackgroundCancer Stem Cells and Immunosuppressive Microenvironment in Glioma
Ma, Q., Long, W., Xing, C., Chu, J., Luo, M., Wang, H. Y., Liu, Q., & Wang, R.-F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02924 · Cited by 219
“Moreover, overexpression of PD-1 on the surface of suppressive cells has been observed in proliferating cancer cells exposed to hypoxia (150).”
BackgroundTumor-associated myeloid cells: diversity and therapeutic targeting
Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C., & Allavena, P. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00613-4 · Cited by 219
Tumor hypoxia: From basic knowledge to therapeutic implications
Liao, C., Liu, X., Zhang, C., & Zhang, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.011 · Cited by 223
Kumar, P., Bhattacharya, P., & Prabhakar, B. S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.08.007 · Cited by 216
Chemoresistance and the Self-Maintaining Tumor Microenvironment
Yeldag, G., Rice, A., & Del Río Hernández, A. (2018) · Cancers · doi:10.3390/cancers10120471 · Cited by 214
“This upregulation suppresses the activation of cytotoxic T cells, and hence promotes immune response evasion [219].”
BackgroundWang, G.-Z., Zhang, L., Zhao, X.-C., Gao, S.-H., Qu, L.-W., Yu, H., Fang, W.-F., Zhou, Y.-C., Liang, F., Zhang, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08887-7 · Cited by 213
Becht, E., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent-Puig, P., Zucman-Rossi, J., Dieu-Nosjean, M.-C., Sautès-Fridman, C., & Fridman, W. H. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213
Noman, M. Z., Hasmim, M., Lequeux, A., Xiao, M., Duhem, C., Chouaib, S., Berchem, G., & Janji, B. (2019) · Cells · doi:10.3390/cells8091083 · Cited by 212
“Hypoxia, via HIF-1α, directly up-regulates the expression of PD-L1 in various tumor cells (melanoma, lung, breast and prostate cancer) by directly binding the HRE in the promoter of PD-L1 gene [33,34].”
BackgroundSelf-citationTrends and Challenges in Tumor Anti-Angiogenic Therapies
Jászai, J., & Schmidt, M. (2019) · Cells · doi:10.3390/cells8091102 · Cited by 208
“Moreover, the hypoxia-induced direct regulation of PD-L1 via HIF1α on immunosuppressive myeloid cells has been recently demonstrated, and its blockade under hypoxia was shown to abrogate myeloid cell-mediated T cell-suppression by modulating cytokine expression [220].”
BackgroundHu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z., He, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1022 · Cited by 211
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
Wang, Y., Wang, H., Yao, H., Li, C., Fang, J.-Y., & Xu, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00536 · Cited by 209
“Research has revealed the co-existence of HIF-1α overexpression, increased PD-L1 level, and repression of T-cell function (Noman et al., 2014; Pollizzi and Powell, 2014; Shehade et al., 2014).”
BackgroundHuman Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity
Elliott, L. A., Doherty, G. A., Sheahan, K., & Ryan, E. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00086 · Cited by 208
“In tumor-bearing mice, hypoxia-induced PD-L1 expression on MDSCs, macrophages, and tumor cells in a hypoxia-inducible factor-1α-dependent manner (124).”
BackgroundHypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Daniel, S. K., Sullivan, K. M., Labadie, K. P., & Pillarisetty, V. G. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0226-9 · Cited by 207
“In mouse models of liver tumors, hypoxia increased PD-L1 expression on MDSCs, which had an immunosuppressive effect on T cells [121].”
BackgroundChauhan, V. P., Chen, I. X., Tong, R., Ng, M. R., Martin, J. D., Naxerova, K., Wu, M. W., Huang, P., Boucher, Y., Kohane, D. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819889116 · Cited by 206
Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB
D’Ignazio, L., Batie, M., & Rocha, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020021 · Cited by 205
“Given the importance of the hypoxic tumour microenvironment for TAMs and tumour-infiltrating myeloid cells, it is not surprising that PD-L1 was identified as a direct HIF-1α target gene in myeloid-derived suppressor cells (MDSCs) [190].”
BackgroundWilson, G. K., Tennant, D. A., & McKeating, J. A. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.025 · Cited by 204
He, Z., & Zhang, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.741305 · Cited by 203
Liu, X.-D., Hoang, A., Zhou, L., Kalra, S., Yetil, A., Sun, M., Ding, Z., Zhang, X., Bai, S., German, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0244 · Cited by 204
Treffers, L. W., Hiemstra, I. H., Kuijpers, T. W., van den Berg, T. K., & Matlung, H. L. (2016) · Immunological Reviews · doi:10.1111/imr.12444 · Cited by 197
“Under normal conditions, neutrophils do not express PD-L1 (184), but its expression can be induced by interferon-gamma (IFN-c) (185) and hypoxia (186), which are readily found in at least some cancers.”
BackgroundAsgarova, A., Asgarov, K., Godet, Y., Peixoto, P., Nadaradjane, A., Boyer-Guittaut, M., Galaine, J., Guenat, D., Mougey, V., Perrard, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423170 · Cited by 199
“myeloid cells infiltrating cancer microenvironment in particular in tumor associated macrophages.(40,41)”
BackgroundAbou Khouzam, R., Brodaczewska, K., Filipiak, A., Zeinelabdin, N. A., Buart, S., Szczylik, C., Kieda, C., & Chouaib, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613114 · Cited by 198
Hypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
Immunoregulatory functions of VISTA
Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Le Mercier, I., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 197
Li, W., Li, F., Zhang, X., Lin, H.-K., & Xu, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00825-8 · Cited by 198
Li, Y., Patel, S. P., Roszik, J., & Qin, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01591 · Cited by 195
“HIFs are a family of transcription factors consisting of three alpha subunits, HIF-1α, HIF-2α, and HIF-3α that can heterodimerize with HIF-1β (11).”
BackgroundInfluentialKaira, K., Higuchi, T., Naruse, I., Arisaka, Y., Tokue, A., Altan, B., Suda, S., Mogi, A., Shimizu, K., Sunaga, N., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3806-1 · Cited by 195
“Based on their results, PD-L1 was suggested as a novel target of HIF-1α, and simultaneous blockade of PD-L1 with the suppression of HIF-1α may be a promising approach for cancer immunotherapy [17].”
BackgroundBarriers to Radiation-Induced In Situ Tumor Vaccination
Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Pilones, K. A., García-Martínez, E., Rudqvist, N.-P., Formenti, S. C., & Demaria, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00229 · Cited by 194
“HIF-1α also regulates MDSCs differentiation and function in the TME (51, 56).”
BackgroundNK cells and solid tumors: therapeutic potential and persisting obstacles
Tong, L., Jiménez-Cortegana, C., Tay, A. H. M., Wickström, S., Galluzzi, L., & Lundqvist, A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01672-z · Cited by 189
“Sarcoma 1 Active, not recruiting 14 Allogenic IL15R agonist Single-arm study NCT02890758 Gastric cancer N/A Recruiting 18 Allogenic Single agent UCB-derived NCT04385641 GBM 1 Not yet recruiting 25 Allogenic Single agent UBC-derived, engineered to resist TGFB1 NCT04991870 GBM 1 Recruiting 5 Autologous Single agent Intr…”
BackgroundInfluentialSchneider, M. A., Heeb, L., Beffinger, M. M., Pantelyushin, S., Linecker, M., Roth, L., Lehmann, K., Ungethüm, U., Kobold, S., Graf, R., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8188 · Cited by 186
Vitamin C and immune cell function in inflammation and cancer
Ang, A., Pullar, J. M., Currie, M. J., & Vissers, M. C. M. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180169 · Cited by 191
“[124]; Mecklenburgh 2002 [98]; Mingay 2018 [55]; Nair 2016 [156]; Nestor 2016 [147]; Nikolouli 2017 [157]; Noh 2005 [173]; Noman 2014 [92]; Northrup 2017 [161]; Oda 2006 [82]; Orlanski 2016 [174]; Palazon 2017 [117]; Perez-Cruz 2003 [103]; © 2018 The Author(s).”
New immunotherapies targeting the PD-1 pathway
Chinai, J. M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., & Zang, X. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.005 · Cited by 189
The roles of glucose metabolic reprogramming in chemo- and radio-resistance
Lin, J., Xia, L., Liang, J., Han, Y., Wang, H., Oyang, L., Tan, S., Tian, Y., Rao, S., Chen, X., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1214-z · Cited by 189
“Moreover, HIF-1α stabilized by hypoxia microenvironment is also able to activate the expression of PD-L1 by binding of HIF to a specific hypoxic response element in the promoter of PD-L1 in cancer cells [127, 128].”
Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy
Guerra, L., Bonetti, L., & Brenner, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107848 · Cited by 189
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
“HIF-1α also directly binds to a hypoxia response element in the promoter of the gene encoding immune checkpoint molecule PD-L1, and hypoxia thereby increases expression of PD-L1 on MDSCs, tumor cells, DCs, and macrophages (144).”
BackgroundContribution of adipose tissue to development of cancer
Cozzo, A. J., Fuller, A. M., & Makowski, L. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170008 · Cited by 188
Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth
Munir, M. T., Kay, M. K., Kang, M. H., Rahman, M. M., Al-Harrasi, A., Choudhury, M., Moustaid-Moussa, N., Hussain, F., & Rahman, S. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126526 · Cited by 188
“In addition, macrophages from hypoxic tumor areas activate HIF-1α, which mediates the expression of inhibitory receptors of T-cell regulation and thus sponsors the dysfunction of tumor-specific T cells [50].”
BackgroundDendritic Cell Metabolism and Function in Tumors
Giovanelli, P., Sandoval, T. A., & Cubillos-Ruiz, J. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.06.004 · Cited by 187
Metadata
- Authors
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Istituto Oncologico Veneto (IT)
- Centre de Recherche Public de la Santé (LU)
- Institut Gustave Roussy (FR)
- University of Verona (IT)
- Unité Institut National de la Santé et de la Recherche Médicale U753, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-04-28
- Volume
- 211
- Issue
- 5
- Pages
- 781-790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4010891
- OpenAlex
- W2149360266
- Semantic Scholar
- dad078dcb463c50f1571acb3306b01954a153c29
- Cited by
- 2,166
- References
- 24
- Citations by year
- 2026: 171 · 2025: 187 · 2024: 208 · 2023: 219 · 2022: 239 · 2021: 331 · 2020: 224 · 2019: 147 · 2018: 139 · 2017: 120 · 2016: 101 · 2015: 61 · 2014: 18
- FWCI
- 48.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, HIF-1α, hypoxia, myeloid-derived suppressor cells, tumor microenvironment, immune checkpoint blockade, T cell activation, hypoxia response element, IL-10, interleukin-6, tumor-associated macrophages, cancer immunotherapy, CTLA-4, PD-1 ligands
- MeSH terms
- Animals, Diamines, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Expression Regulation, Luciferases, Lymphocyte Activation, Mice, Inbred C57BL, Organic Chemicals, Quinolines, T-Lymphocytes, Cell Hypoxia, Myeloid Cells, RNA Interference, Chromatin Immunoprecipitation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Benzothiazoles, Tumor Microenvironment, Real-Time Polymerase Chain Reaction, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.